Program
Ezetimibe
Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.
Drug pageEzetimibe: every studyMany companies study it; this page follows only the 97 they lead. All 208 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 710 open or running | phase 4since Sep 7, 2005 | Sep 23, 2004 | none ahead |
| Daiichi Sankyo | 61 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | Jun 1, 2028phase 3 · NCT07474649 |
| Yuhanits history only | 40 open or running | phase 4since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| IlDong Pharmaceuticalits history only | 20 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| JW Pharmaceuticalits history only | 21 open or running | phase 4since Feb 18, 2026 | Oct 6, 2020 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Oct 10, 2006 | Sep 12, 2005 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Merckits history only | 10 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| NVP Healthcareits history only | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| Shin Poong Pharmaceuticalits history only | 10 open or running | phase 3since Aug 18, 2017 | Aug 18, 2017 | none ahead |
Also a collaborator on its studies: Pharma Medica Research, Regeneron Pharmaceuticals, Merck Frosst Canada, Linical Korea and Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2005First study: phase 4 study in HypercholesterolemiaFirst studyNCT00185107 · 45 enrolled · United States
- Sep 11, 20252 phase 1 studies in Healthy SubjectsNCT07182383, NCT07201545
- Nov 14, 20252 phase 1 studies in Healthy SubjectsNCT07235189, NCT07268625
- Mar 11, 2026Phase 3 study in Coronary Artery DiseaseNCT07474649 · 103 planned · Germany, Italy, Spain
Ahead
- Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseNCT07474649
TargetBeta
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule
Studies
All 6 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07474649Coronary Artery Disease · Germany, Italy, Spain | 3 | Recruiting | Jun 1, 2028 | 103 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Jan 28, 2026 | 58 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Nov 24, 2025 | 58 |
| NCT00185107Hypercholesterolemia · United States | 4 | Completed | 45 |
How it is read
Names in the registry
- “Ezetimibe”, 31 entries
- “ezetimibe”, 11 entries
- “ezetimibe (+) simvastatin”, 10 entries
- “MK0653, ezetimibe”, 7 entries
- “CKD-828, D097, D337”, 6 entries
Codes read as this program: MK0653.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 73 studies
- Hypertension, 9 studies
- Hyperlipidemias, 7 studies
- Lipid Metabolism, Inborn Errors, 3 studies
- Atherosclerosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.